Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Kato GJ, Gladwin MT, Steinberg MH.

Blood Rev. 2007 Jan;21(1):37-47. Epub 2006 Nov 7. Review.

2.

Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.

Hsu LL, Champion HC, Campbell-Lee SA, Bivalacqua TJ, Manci EA, Diwan BA, Schimel DM, Cochard AE, Wang X, Schechter AN, Noguchi CT, Gladwin MT.

Blood. 2007 Apr 1;109(7):3088-98. Erratum in: Blood. 2008 Feb 15;111(4):1772.

3.

Evolution of novel small-molecule therapeutics targeting sickle cell vasculopathy.

Kato GJ, Gladwin MT.

JAMA. 2008 Dec 10;300(22):2638-46. doi: 10.1001/jama.2008.598. Review.

4.

Sickle cell disease vasculopathy: a state of nitric oxide resistance.

Wood KC, Hsu LL, Gladwin MT.

Free Radic Biol Med. 2008 Apr 15;44(8):1506-28. doi: 10.1016/j.freeradbiomed.2008.01.008. Epub 2008 Jan 26. Review.

PMID:
18261470
5.

Low micromolar intravascular cell-free hemoglobin concentration affects vascular NO bioavailability in sickle cell disease: a computational analysis.

Deonikar P, Kavdia M.

J Appl Physiol (1985). 2012 Apr;112(8):1383-92. doi: 10.1152/japplphysiol.01173.2011. Epub 2012 Jan 5.

6.

Priapism in sickle-cell disease: a hematologist's perspective.

Kato GJ.

J Sex Med. 2012 Jan;9(1):70-8. doi: 10.1111/j.1743-6109.2011.02287.x. Epub 2011 May 6. Review.

7.

Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease.

Kato GJ, McGowan V, Machado RF, Little JA, Taylor J 6th, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris SM Jr, Gladwin MT.

Blood. 2006 Mar 15;107(6):2279-85. Epub 2005 Nov 15.

8.

Sickle cell anemia and vascular dysfunction: the nitric oxide connection.

Akinsheye I, Klings ES.

J Cell Physiol. 2010 Sep;224(3):620-5. doi: 10.1002/jcp.22195. Review.

PMID:
20578237
9.

Hemolysis-associated priapism in sickle cell disease.

Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH.

Blood. 2005 Nov 1;106(9):3264-7. Epub 2005 Jun 28.

10.

Sickle cell disease at the dawn of the molecular era.

Abboud MR, Musallam KM.

Hemoglobin. 2009;33 Suppl 1:S93-S106. doi: 10.3109/03630260903347617. Review.

PMID:
20001639
11.

Plasma asymmetric dimethylarginine concentrations in sickle cell disease are related to the hemolytic phenotype.

Landburg PP, Teerlink T, Biemond BJ, Brandjes DP, Muskiet FA, Duits AJ, Schnog JB; CURAMA study group.

Blood Cells Mol Dis. 2010 Apr 15;44(4):229-32. doi: 10.1016/j.bcmd.2010.02.005. Epub 2010 Feb 24.

PMID:
20185345
12.

Sickle Cell Disease.

Bender MA, Douthitt Seibel G.

In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017.
2003 Sep 15 [updated 2014 Oct 23].

13.

Mechanisms of vasculopathy in sickle cell disease and thalassemia.

Morris CR.

Hematology Am Soc Hematol Educ Program. 2008:177-85. doi: 10.1182/asheducation-2008.1.177. Review.

PMID:
19074078
14.

Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.

Villagra J, Shiva S, Hunter LA, Machado RF, Gladwin MT, Kato GJ.

Blood. 2007 Sep 15;110(6):2166-72. Epub 2007 May 29.

15.

Pulmonary hypertension and nitric oxide depletion in sickle cell disease.

Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE.

Blood. 2010 Aug 5;116(5):687-92. doi: 10.1182/blood-2010-02-268193. Epub 2010 Apr 15. Review.

16.

Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.

Gladwin MT, Kato GJ.

Hematology Am Soc Hematol Educ Program. 2005:51-7.

17.

Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain.

Taylor JG 6th, Nolan VG, Mendelsohn L, Kato GJ, Gladwin MT, Steinberg MH.

PLoS One. 2008 May 7;3(5):e2095. doi: 10.1371/journal.pone.0002095.

18.

[Pathophysiological consequences of hemolysis. Role of cell-free hemoglobin].

Misztal T, Tomasiak M.

Postepy Hig Med Dosw (Online). 2011 Sep 28;65:627-39. Review. Polish.

19.

Markers of endothelial dysfunction differ between subphenotypes in children with sickle cell disease.

van der Land V, Peters M, Biemond BJ, Heijboer H, Harteveld CL, Fijnvandraat K.

Thromb Res. 2013;132(6):712-7. doi: 10.1016/j.thromres.2013.10.006. Epub 2013 Oct 12.

20.

Pulmonary complications of sickle cell disease.

Gladwin MT, Vichinsky E.

N Engl J Med. 2008 Nov 20;359(21):2254-65. doi: 10.1056/NEJMra0804411. Review. No abstract available.

PMID:
19020327

Supplemental Content

Support Center